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Abstract
Objective To clarify associations of fish consumption and long chain
omega 3 fatty acids with risk of cerebrovascular disease for primary and
secondary prevention.
Design Systematic review and meta-analysis.
Data sources Studies published before September 2012 identified
through electronic searches using Medline, Embase, BIOSIS, and
Science Citation Index databases.
Eligibility criteria Prospective cohort studies and randomised controlled
trials reporting on associations of fish consumption and long chain omega
3 fatty acids (based on dietary self report), omega 3 fatty acids
biomarkers, or supplementations with cerebrovascular disease (defined
as any fatal or non-fatal ischaemic stroke, haemorrhagic stroke,
cerebrovascular accident, or transient ischaemic attack). Both primary
and secondary prevention studies (comprising participants with or without
cardiovascular disease at baseline) were eligible.
Results 26 prospective cohort studies and 12 randomised controlled
trials with aggregate data on 794 000 non-overlapping people and 34
817 cerebrovascular outcomes were included. In cohort studies
comparing categories of fish intake the pooled relative risk for
cerebrovascular disease for 2-4 servings a week versus ≤1 servings a
week was 0.94 (95% confidence intervals 0.90 to 0.98) and for ≥5
servings a week versus 1 serving a week was 0.88 (0.81 to 0.96). The
relative risk for cerebrovascular disease comparing the top thirds of
baseline long chain omega 3 fatty acids with the bottom thirds for
circulating biomarkers was 1.04 (0.90 to 1.20) and for dietary exposures
was 0.90 (0.80 to 1.01). In the randomised controlled trials the relative
risk for cerebrovascular disease in the long chain omega 3 supplement
compared with the control group in primary prevention trials was 0.98
(0.89 to 1.08) and in secondary prevention trials was 1.17 (0.99 to 1.38).
For fish or omega 3 fatty acids the estimates for ischaemic and
haemorrhagic cerebrovascular events were broadly similar. Evidence
was lacking of heterogeneity and publication bias across studies or within
subgroups.
Conclusions Available observational data indicate moderate, inverse
associations of fish consumption and long chain omega 3 fatty acids
with cerebrovascular risk. Long chain omega 3 fatty acids measured as
circulating biomarkers in observational studies or supplements in primary
and secondary prevention trials were not associated with cerebrovascular
disease. The beneficial effect of fish intake on cerebrovascular risk is
likely to be mediated through the interplay of a wide range of nutrients
abundant in fish.
Introduction
Fish consumption is considered one of the key components of
a cardioprotective diet.1Current cardiovascular guidelines2 3 for
healthy individuals encourage consumption of a variety of fish,
preferably oily types, at least twice a week. Cold water oily fish
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and fish oil are also the most common dietary sources of long
chain omega 3 fatty acids, a group of polyunsaturated fats that
primarily include eicosapentaenoic acid and docosahexaenoic
acid.4 Studies show that regular consumption of both these fats
as supplementsmay reduce arrhythmias, endothelial dysfunction,
circulating triglyceride levels, and inflammation.5 6 Such findings
have prompted clinical guidelines to recommend the use of
these nutrients in people with pre-existing coronary heart disease
or high blood levels of triglycerides.7 8 Whether, or to what
extent, current recommendations for consumption of fish or
long chain omega 3 fatty acids may apply to cerebrovascular
diseases is, however, unclear. Observational evidence on
consumption of fish and omega 3 fatty acid is inconsistent for
cerebrovascular outcomes.9 Likewise, despite a growing body
of experimental evidence on eicosapentaenoic acid and
docosahexaenoic acid supplements, the results for cardiovascular
prevention are conflicting. Whereas earlier trials reported
moderate protective effects on coronary heart disease and sudden
cardiac death outcomes,10 11 recent large scale primary and
secondary prevention trials failed to show the efficacy of
supplementation with long chain fatty acids in reducing
cardiovascular diseases.12 13 Therefore, whether supplementing
with long chain omega 3 fatty acids could specifically help
prevent stroke, remains elusive.
Several studies have investigated the intake of fish and long
chain omega 3 fatty acids in relation to cerebrovascular
disease.14-21 However, these studies varied in methodology (for
example, self reported dietary intake of omega 3 fatty acids
versus circulating biomarkers versus supplements), scientific
rigour (for example, sufficient power and duration of follow-up),
or the ability to evaluate associations in greater detail (for
example, by stroke subtypes). Furthermore, previous
meta-analyses22-24 dealing with these hypotheses did not assess
important differences in the exposure type, such as white versus
fatty fish consumption, within clinically relevant subgroups (for
example, average intake or stroke subtypes); and did not
systematically compare observational evidence in the context
of experimental data in a single investigation.
We systematically reviewed andmeta-analysed available studies
to quantify the associations of fish consumption with total and
cause specific cerebrovascular disease in prospective cohort
studies; examined associations of dietary and circulating levels
of long chain omega 3 fatty acids with cerebrovascular diseases
in observational studies; and evaluated the potential effects of
their supplementations on future cerebrovascular events in
randomised controlled trials.
Methods
We carried out an electronic search using primarily Medline,
supplemented by searches of Embase, BIOSIS, and the Science
Citation Index databases, for studies published before September
2012, without any language restriction (see supplementary file
for details of the search strategy). Potentially eligible studies
were those that had reported associations of fish (defined as fish
and other seafood) or omega 3 fatty acids consumption,
circulating omega 3 fatty acids, and omega 3 fatty acid
supplements or dietary fish interventions with cerebrovascular
disease (defined as any fatal or non-fatal ischaemic stroke,
haemorrhagic stroke, cerebrovascular accident, or transient
ischaemic attack). In the computer based searches we combined
search terms related to the exposure (for example, fish, fatty
acids, omega 3 fatty acids) and outcomes of interest (stroke,
cerebrovascular disorders, etc). We considered prospective
cohort studies to be eligible for inclusion if they had at least
one year of follow-up and involved either general populations
(participants not selected on the basis of pre-existing disease)
or people at high risk of cardiovascular disease (those selected
on the basis of high risk factors for cardiovascular disease or
pre-existing cardiovascular disease, or both). Randomised
intervention studies were eligible for inclusion if they assessed
the effects of long chain omega 3 fatty acids supplements or
dietary fish consumption in adults; collected “hard”
cerebrovascular disease endpoints, such as fatal or non-fatal
ischaemic stroke, or fatal or non-fatal haemorrhagic stroke; and
followed participants for at least one year. Two independent
reviewers screened the titles, abstracts, and full texts of the
initially identified studies to determine eligibility. Disagreements
were resolved through consensus or consultation with a third
author. To identify additional publications we searched the
reference lists of all retrieved studies.
Data collection process and data items
Two independent reviewers used a predesigned data abstraction
form to extract relevant information from the selected studies.
The form included questions on study size, study design,
baseline population (general populations or those at high risk
of cardiovascular disease), geographical location, year of
baseline survey, age range of participants at baseline, duration
of follow-up, reported degree of adjustment for potential
confounders (defined as “+” when relative risks were adjusted
for age and sex, “++” after further adjustment for conventional
vascular risk factors (for example, smoking status, history of
diabetes, and hypertension), and “+++” when further adjusted
for other additional variables (for example, social class or total
energy intake), type and numbers of cerebrovascular disease
outcomes, and reported relative risks for each outcome. Where
appropriate we extracted information on type of fish (white or
fatty), amount consumed daily, dietary assessment tool (dietary
questionnaire, defined as food frequency or diet history
questionnaires; diet records, defined as all open ended
instruments such as 24 hour recall and food diaries), blinding
status, and type and composition of supplement or placebo. In
the case of multiple publications, we abstracted the most up to
date or most comprehensive information.
Quality evaluation assessment
Two independent investigators evaluated the quality of the
included studies by using a modified scoring system based on
MOOSE, QUATSO, and STROBE guidelines.25-27 This allowed
a total score from 0 to 6 points (6 representing the highest
quality), with 1 point allocated if a study provided a study
rationale; used appropriate selection criteria; employed a
validated questionnaire (dietary studies) or assay method (blood
based studies), or involved adequate blinding (randomised
controlled trials); collected outcomes not solely based on self
report; reported findings adjusted for age, sex, body mass index,
and smoking status; and additionally adjusted for other
covariates, such as social status and other nutrients.
Statistical analysis
To limit potential biases, the analyses involved only comparisons
within studies (participants being directly compared only within
each cohort). To enable a consistent approach to analyses, where
appropriate, we transformed risk estimates from each prospective
cohort study to enable comparisons between the top and bottom
third of the population’s baseline distribution of exposure values,
using methods previously described.28 Briefly, we transformed
log risk estimates assuming a normal distribution, with the
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comparison between top and bottom thirds being equivalent to
2.18 times the log risk ratio for a 1 standard deviation increase
(or equivalently as 2.18/2.54 times the log risk ratio for a
comparison of extreme quarters). We calculated standard errors
of the log risk ratios using published confidence limits and then
standardised them in the sameway. Hazard and odds ratios were
assumed to approximate the same measure of relative risks.
Using a random effects model that included between study
heterogeneity, we calculated summary relative risks by pooling
the study specific estimates. Where studies reported relative
risks with differing degrees of adjustment for other risk factors,
we used the maximum adjusted estimate. Dose-response
meta-analysis of fish consumption and cerebrovascular risk was
done using methods previously reported,24 29 which facilitated
the calculation of a pooled relative risk across studies with a
common unit of comparison within studies (the relative risk
associated with a two incremental serving a week in this review),
assuming a linear dose-response relation. Assessments for
standardised categories of fish consumption (2-4 times a week
and ≥5 times a week) and cerebrovascular risk compared with
a reference category (≤1 a week) were based on combining
comparable relative risk estimates across studies using random
effects meta-analyses.22 As reference groups of the included
studies varied (that is, from 0 to ≤1 times/week), in this analysis,
we defined “≤1/week” as the reference category assuming that
all reported reference exposures represent an equally low level
of intake. Consistency of findings across studies was assessed
by standard χ2 tests and the I2 statistic.30 Heterogeneity was
quantified by comparing results from studies grouped according
to prespecified study level characteristics using metaregression.
Evidence of publication bias was assessed using funnel plots
and the Egger test.31All statistical tests were two sided and used
a significance level of P<0.05. Analyses were done using Stata
release 11.
Results
The search strategy identified 4343 unique citations. After the
initial screening, based on titles and abstracts, 447 articles
remained for further evaluation. Following detailed assessments,
402 articles were excluded (fig 1⇓). Overall, 45 articles based
on 38 unique studies met the inclusion criteria and were included
in the meta-analysis (see supplementary file). All relevant
studies identified were published in the English language. In
aggregate, the included studies comprised 794 000 unique
participants and 34 817 incident cerebrovascular disease
outcomes from 15 countries (table⇓ and supplementary tables).
Fish consumption and cerebrovascular risk
Information on fish consumption and cerebrovascular disease
were available in 21 prospective cohort studies, totalling 675
048 participants and 25 320 incident cerebrovascular events
(see supplementary table 1). All 21 studies were based on
general populations. Seven involved participants from Europe,
seven from North America, and seven from the Asia-Pacific
region. Six studies included only men, three only women, and
the rest both sexes. The relative risk of cerebrovascular disease
for standardised categories of fish intake, typically adjusted for
several conventional risk factors, for 2-4 versus ≤1 servings a
week was 0.94 (95% confidence interval 0.90 to 0.98) and for
≥5 versus ≤1 servings a week was 0.88 (0.81 to 0.96) (based
on 18 and eight studies, respectively; fig 2⇓ and supplementary
figs 1 and 2). There was no evidence of heterogeneity across
studies (I2=20-22%, P>0.05 for both, see supplementary figs 1
and 2). In the dose-response meta-analysis (18 studies), an
increment of two servings a week of any fish was associated
with a 4% (95% confidence interval 1% to 7%) reduced risk of
cerebrovascular disease (fig 2 and supplementary fig 3). For all
21 studies the relative risk when comparing participants in the
highest with the lowest category of fish intake was 0.88 (0.84
to 0.93, see supplementary fig 4). In a subset of studies (62 799
participants) the corresponding relative risk for white fish types
was 1.03 (0.90 to 1.19) and for fatty fish types was 0.84 (0.72
to 0.98, see supplementary fig 5).
Comparison with evidence from long chain
omega 3 fatty acid studies
Fourteen prospective studies reported on long chain omega 3
fatty acids in relation to risk of cerebrovascular disease,
involving 305 119 participants and 5374 cerebrovascular
outcomes recorded during an average follow-up ranging from
four to 30 years (see supplementary table 2). Ten studies
reported on intake of dietary long chain omega 3 fatty acid,
whereas four were based on circulating blood compositions of
omega 3. Five studies involved participants from Europe, four
from North America, and five from the Asia-Pacific region.
Seven studies concerned both sexes, five only men, and two
only women. All cohorts included healthy populations at
baseline. Fig 3⇓ and supplementary figs 6 and 7 present the
relative risks for cerebrovascular disease for participants in the
top compared with bottom third of baseline long chain omega
3 fatty acid and fish consumption. Relative risks for long chain
omega 3 fatty acids measured as circulating biomarkers and self
reported dietary exposures were 1.04 (95% confidence interval
0.90 to 1.20) and 0.90 (0.80 to 1.01), respectively. The
corresponding relative risk in the top compared with bottom
third of baseline fish consumption (11 studies; 366 787
participants) was 0.91 (0.86 to 0.97). Similar results were
obtained for ischaemic and haemorrhagic stroke events (fig 3
and supplementary figs 8 and 9).
Effects of long chain omega 3 fatty acid
supplements on cerebrovascular risk
Twelve randomised controlled trials totalling 62 040 participants
reported on long chain omega 3 fatty acids supplementation and
cerebrovascular disease (see supplementary table 3). No study
assessed the effects of any dietary fish interventions. Most of
these randomised controlled trials (nine out of 12) were done
in Europe. Ten trials included participants with previous
cardiovascular disease, whereas two concerned populations
without any pre-existing cardiovascular disease at baseline.
Participants in the intervention arm on average consumed 1.8
g of long chain omega 3 fatty acids daily (range 0.4-6.0 g/day),
where an oil capsule was the principle form of supplementation.
After an average follow-up of 3.0 (range 1.0-4.7 years) years,
a total of 800 cerebrovascular events occurred among
participants in the intervention group compared with 763 events
in the control group, with a pooled relative risk of 1.03 (95%
confidence interval 0.94 to 1.12; fig 4⇓). No evidence of
heterogeneity was found among these randomised controlled
trials (I2=3.5%, P=0.41, also see supplementary fig 10). The
corresponding pooled relative risk for primary prevention trials
(two studies) was 0.98 (0.89 to 1.08) and for secondary
prevention trials (10 studies) was 1.17 (0.99 to 1.38, fig 4 and
supplementary fig 10). The relative risks were broadly similar
across baseline population and for cause specific cerebrovascular
outcomes based on studies with available data (fig 4 and
supplementary fig 10).
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Stratified and sensitivity analyses
The overall associations observed in prospective studies for
consumption of fish and long chain omega 3 fatty acids remained
broadly consistent when these studies were grouped by several
characteristics at study level. For instance, the overall relative
risk of cerebrovascular disease when comparing the highest
with the lowest category of fish intake was 0.87 (95%
confidence interval 0.82 to 0.92) and for studies with higher
and lower average fish consumption was 0.89 (0.78 to 1.01) (P
for heterogeneity >0.05; see supplementary fig 11). Similarly,
comparing studies with higher versus lower average
consumption of long chain omega 3 fatty acids yielded relative
risks of 0.93 (0.81 to 1.07) and 0.85 (0.72 to 1.01), respectively
(P for heterogeneity >0.05, also see supplementary fig 12a). For
consumption of both fish and omega 3 fatty acids in cohort
studies, the magnitude of the relative risks of cerebrovascular
disease for women seemed larger than those for men. In the
randomised controlled trials there was also no clear evidence
of heterogeneity according to several trial characteristics (for
example, amount and type of intervention, blinding status, trial
size, or duration of follow-up), except for some evidence that
larger studies tended to yield more extreme relative risks (see
supplementary fig 12b). In both observational and experimental
studies, subgroup analyses indicated no geographical variation
for the associations.
Analysis of publication bias
There was no evidence of publication bias across prospective
cohort studies of fish or long chain omega 3 fatty acid
consumption and the randomised controlled trials included in
this review (P>0.05 in Egger’s asymmetry test for all, also see
supplementary fig 13).
Discussion
This review found that higher fish consumption is moderately
but significantly associated with a reduced risk of incident
cerebrovascular disease. By contrast, dietary, circulating
biomarkers and supplements of long chain omega 3 fatty acids
were not significantly associated with risk of cerebrovascular
disease. The combined estimates remained similar for cause
specific cerebrovascular events. The associations for long chain
omega 3 fatty acids were consistent across people with and
without pre-existing cardiovascular disease—indicating a
potential lack of benefit for either primary or secondary
prevention of cerebrovascular disease. These findings therefore
suggest that single nutrients may have limited effects on chronic
disease outside of their original food sources.
The results observed in our review for fish consumption and
cerebrovascular risk may have several alternative explanations.
Firstly, it is possible that the potential benefit of fish
consumption could in addition to long chain omega 3 fatty acids
be attributed to a wider array of nutrients (and their interaction)
that are abundant in fish. For example, fish are also a good
source of vitamins D and B complex, which have been linked
to inverse cerebrovascular risk.32 33 In addition, essential amino
acids and trace elements in fish (for example, taurine,34 35
arginine,36 selenium,37 calcium,38 magnesium,39 40 potassium,41
and iodine42) may have potentially favourable vascular effects.
Secondly, the positive impact of fish could be explained by a
concomitant reduction in intake of foods detrimental to
cerebrovascular health, such as red meat. Adjustment for
confounding by other dietary factors is often inadequate and
rarely accounts for such “protein substitution effect.”43 None
the less, in a recent analysis based on two large cohorts in the
United States, a 17% reduction in cerebrovascular risk was
observed when redmeat intake was replaced with fish.43Thirdly,
higher fish consumption may simply be an indicator of a
healthier dietary pattern or higher socioeconomic status, which
themselves are associated with conventional vascular
determinants and outcomes.16 44Although our subgroup analyses
by levels of adjustment were consistent with the overall
estimates, this may not fully address the potential issue of
residual confounding, as individual characteristics such as
baseline vascular drug use (antihypertensives, statins, aspirin,
etc) or level of adherence (for instance for omega 3 supplements
in randomised controlled trials) were generally unavailable in
the studies included in the meta-analysis. The differences
observed for the associations between white and fatty fish may
be explained by the distinct ways in which the two foods are
typically prepared. Studies that contributed to these analyses
were exclusively based on the United Kingdom,17where dietary
questionnaires for the white fish items usually include battered
and deep fried white fish; and in Sweden, where frying is the
most common cooking method for white fish.15 This systematic
difference in the preparation of white fish, in contrast with that
of oily fish, could explain the null effect because potentially
detrimental fats (such as trans fatty acids) are added during the
cooking process.45
The discordant results observed for long chain omega 3 fatty
acids compared with overall fish intake may also have various
potential explanations. Firstly, food composition tables are often
incomplete such that the long chain omega 3 fatty acid content
of foods is unknown, which may lead to underestimation of the
true intake of long chain omega 3 fatty acids. For example, only
65% of all foods in the US Department of Agriculture food
composition database reportedly have a value for their omega
3 fatty acid content.46 Additionally, these databases may not
account for all variations in the omega 3 fatty acid content of
fish from different environments47 (for example, cooking
methods, dietary patterns, or farm raised food versus wild
sources).7 Secondly, self reported dietary questionnaires typically
seek information on fish group rather than on specific fish types
(for instance, oily fish versus salmon). Considering the
substantial differences in quantity of omega 3 fatty acids
between marine species,48 this inaccurate grouping of fish may
lead to potential poor allocation of nutrient composition to food
and overall misclassification of omega 3 fatty acid intake, which
may attenuate the associations. Thirdly, although fish intake
generally correlates highly with circulating blood omega 3 fatty
acid levels, in the general Western population only 20-25% of
the variation in such levels might be explained by fish
consumption alone.49 This may be responsible, at least in part,
for the inconsistent results between observational studies
concerning fish and long chain omega 3 fatty acids. Fourthly,
in our analyses circulating biomarkers of long chain omega 3
fatty acids were not associated with cerebrovascular disease.
Although blood fatty acid levels are not affected by limitations
in the dietary instruments or composition databases, these
biomarkers only reflect exposures over the previous few weeks
compared with a prolonged assessment that is more relevant to
predict chronic disease risk.50 Finally, none of the randomised
controlled trials were designed to investigate cerebrovascular
disease as the primary outcome of interest. Therefore, competing
risk events such as coronary heart disease may have altered the
probability of cerebrovascular outcomes and impeded many
subsequent events being considered thus limiting sufficiently
powerful analyses. Furthermore, discrepant findings on omega
3 fatty acids in observational studies and randomised controlled
trials may be partly explained by the inherent differences
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between baseline populations in the two designs—that is,
generally healthy people compared with people with previous
vascular disease or higher cardiovascular disease risk factors,
respectively.
Comparison with previous studies
Findings of this updated meta-analysis generally concur and
further extend the findings of previous reviews in several
important ways. Our meta-analysis reinforces earlier results by
including several recently published large scale prospective
cohort studies. Our analyses on prospective dietary fish studies,
for example, involved twice as many cerebrovascular events as
the two previous reviews combined.22 24 Similarly, analyses on
long chain omega 3 fatty acids based on data from observational
studies and trials had about 10 times as many stroke events as
the previous analysis.23 The current review also evaluates the
potential effects of long chain omega 3 supplements on
cerebrovascular risk by comparing observational evidence in
the context of experimental data, systematically in a single
investigation. Additionally, it comprehensively records a wide
range of clinically relevant subgroups to carry out the most
detailed exploration of potential heterogeneity than previously
reported.
Implications of findings
Our findings may have several implications. They reinforce a
potentially modest beneficial role of fish intake in the cause of
cerebrovascular disease. Such an advantage was less evident
for long chain omega 3 fatty acids in both observational studies
and interventions targeting primary and secondary stroke
prevention. Our findings are in line with current dietary
guidelines (that is, to encourage fish consumption for all; and
intake of fish oils, preferably from oily fish, to people with
pre-existing or at high risk of coronary heart disease) and favour
propositions that the future nutritional guidelines should be
principally “food based.”51 They also underscore scientific gaps
in the experimental evidence, specifically the lack of studies
involving healthy populations and interventions targeting fish
intake rather than using supplements, which may have different
mechanistic effects. Additionally, adequately powered data from
trials will be essential to investigate reliably the apparent higher
risk of cerebrovascular disease observed in the secondary
prevention trials of long chain omega 3 fatty acid supplements,
and potential sex specific associations across observational
studies.
Strengths and limitations of this review
The strengths and limitations of this reviewmerit consideration.
We included data from almost 800 000 participants from 15
countries. There was limited evidence of heterogeneity and
publication bias across studies or within subgroups. In the
absence of individual patient level data, we used standardised
risk estimates to allow consistent comparisons and we examined
several clinically relevant characteristics to reduce potential
heterogeneity. However, the current review was limited by an
overall lack of available data on the cause specific
cerebrovascular outcomes. For example, only a few studies
reported more than 1000 ischaemic stroke events, whereas most
involved analyses primarily on composite cerebrovascular
events. Furthermore, even in aggregate, fewer than 2000
cerebrovascular events were available in the randomised
controlled trials and none of them were based on healthy
populations.
Conclusions
Available observational data demonstrate moderate, inverse
associations of fish and long chain omega 3 fatty acids
consumption with risk of cerebrovascular events. However,
there was no evidence for similar inverse associations with
cerebrovascular disease for long chain omega 3 fatty acids
measured as circulating biomarkers in observational studies, or
supplements in primary and secondary prevention trials. The
beneficial effect of fish intake on cerebrovascular risk might be
mediated through a complex interplay among a wide range of
nutrients commonly found in fish.
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Table
Table 1| Summary of data included in systematic review
No of incident cerebrovascular
eventsAverage follow-up (years)Total No of participantsNo of studiesStudy types
Prospective cohort studies
26 56915.0731 96026All studies*:
25 32015.1675 04821Fish
537413.0305 11914Long chain omega 3 fatty acids
1563‡3.062 040†12RCTs of long chain omega 3 fatty acid
supplementation
34 817794 00038Total unique studies
General characteristics of individual studies are described in detail in the supplementary tables.
RCT=randomised controlled trial.
*Nine studies reported on consumption of both fish and long chain omega 3 fatty acids.
†Includes 31 088 and 30 952 total participants in intervention and control groups, respectively.
‡Includes 800 and 763 cerebrovascular disease events in intervention and control groups, respectively.
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Figures
Fig 1 Flow of studies in review
Fig 2 Association between fish consumption and risk of cerebrovascular disease in prospective cohort studies with information
on intake categories and weekly increment of servings
Fig 3 Association of long chain omega 3 fatty acids and fish consumption with cerebrovascular disease, based on prospective
cohort studies, comparing risk in top versus bottom third of baseline levels. *To allow consistent indirect comparison, includes
prospective cohort studies with available risk estimates comparing top versus bottom thirds of fish consumption
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Fig 4 Effects of long chain omega 3 fatty acid supplementations on cerebrovascular disease, derived from randomised
control trials. *Trials involving participants with no pre-existing cardiovascular disease at baseline. †Trials including participants
with previous or existing cardiovascular disease at baseline. ‡Based on studies with available information on subtype
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